viral load

ATV006 has antiviral activity and can be used in research on the treatment of viral infections.

Ziresovir (RO-0529/AK0529) belongs to small molecule inhibitors and is a respiratory syncytial virus (RSV) fusion protein (F protein) inhibitor (EC50 = 3 nM) with oral activity and selectivity. This compound is used in research on respiratory syncytial virus infection, significantly alleviating bronchitis symptoms and reducing viral load.

Netivudine is a potent nucleoside reverse transcriptase inhibitor (NRTIs), a nucleoside analogue with anti-varicella zoster virus activity that can be used to treat human immunodeficiency virus (HIV) infection. Netivudine works by inhibiting reverse transcriptase, which reduces viral load in the body and slows the progression of the disease through its inhibitory effect.

Zanamivir amine, a neuraminidase inhibitor, exhibits antiviral activity by effectively curbing the proliferation of influenza viruses. Clinically, it is utilized to suppress influenza infections by interfering with the viral replication process, thereby reducing viral load.

MSRV-IN-1 (Compound M3) is an inhibitor targeting aquatic rhabdoviruses, including MSRV, SVCV, and IHNV, with IC50 values of 0.92 μM, 2.92 μM, and 2.78 μM, respectively. Instead of acting directly on virus particles, MSRV-IN-1 disrupts the replication environment by altering the virus-induced S-phase cell cycle arrest, inhibiting viral replication. Administered via intraperitoneal injection at a dose of 20 mg/kg, MSRV-IN-1 significantly improves the survival rate of MSRV-infected largemouth bass by 35.98% and reduces viral load in the liver, spleen, and kidneys. MSRV-IN-1 is applicable in research on rhabdovirus-associated diseases in aquaculture.

TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 μM) and TLR8 (LEC [hTLR8] of 1.6 μM). It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 μM). In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFNα, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.

Ganglioside GM1 asialo is a component of cellular lipid rafts and can be formed by the cleavage of the sialic acid residue from ganglioside GM1 by neuraminidase. Ganglioside GM1 asialo is a glycolipid receptor for P. aeruginosa flagellin and stimulates defensive responses in host cells, including extracellular ATP release, calcium mobilization, and ERK1/2 phosphorylation when stimulated by flagellin and an anti-ganglioside GM1 asialo antibody. The percentage of ganglioside GM1 asialo-positive natural killer (NK) and CD8+ T cells in lung is increased in a mouse model of respiratory syncytial virus (RSV) infection compared with healthy animals. Depletion of ganglioside GM1 asialo-positive NK and T cells reduces IFN-γ levels in the lung, reduces weight loss, and increases lung viral load in RSV-infected mice. Ganglioside GM1 asialo mixture contains ganglioside GM1 asialo molecular species with C18:1 and C20:1 sphingoid backbones.

Ruzotolimod (RO7020531) is an orally active Toll-like receptor 7 agonist that suppresses WHV replication and, in combination with RO-7049389, significantly reduces AAV-HBV viral load, while also serving as an experimental immunomodulatory agent for studying antiviral innate immune responses and therapeutic strategies relevant to SARS-CoV-2 and COVID-19 infection models.

Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. Efficacy of remdesivir against Ebola virus has been demonstrated. Remdesivir inhibits SARS-CoV-2 replication, reduces viral load, and exerts protective effects in SARS-CoV-2 infected animals. Remdesivir also reduces the pathological process, alleviates mild symptoms, and improves pulmonary lesions in SARS-CoV-2-infecetd animals. Remdesivir has been used as a compassionate drug for treating COVID-19 patients. *******WARNING****** Our product remdesivir is a pure chemical solid powder which is only for laboratory research use, NOT FOR HUMAN OR PATIENT USE

Ansuvimab is a humanizing neutralizing monoclonal antibody targeting the glycoprotein (GP) of Zaire ebolavirus (EBOV). The antibody specifically binds to a highly conserved epitope (LEIKKPDGS) within the receptor-binding site of the EBOV GP1 subunit, effectively blocking the interaction between the viral glycoprotein and the host intracellular Niemann-Pick C1 (NPC1) receptor. In addition to its neutralizing activity, Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) to facilitate the clearance of infected cells by the immune system. As the first approved treatment for Ebola virus infection, it possesses significant clinical value in reducing viral load and improving patient survival rates.

Casirivimab (REGN10933), a human monoclonal antibody targeting the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging variants. When combined with Imdevimab, it significantly lowers viral load and enhances disease outcomes [1].

Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1].

Suvizumab is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.

Olgotrelvir is an antiviral agent [1]. It inhibits viral replication by targeting key viral enzymes, thereby reducing the viral load in infected cells. The compound exhibits specificity for its target enzymes, which minimizes off-target effects and enhances its therapeutic profile. Clinical studies demonstrate its efficacy against a range of viral pathogens.

ATV041, an orally active compound that combines features of Ibuprofen and nucleotide analogues, enhances the oral pharmacokinetic (PK) profile and tissue distribution, exhibiting anti-mouse hepatitis virus (MHV) activity. The compound demonstrates a dose-dependent reduction in viral load, tissue damage, and virus-induced inflammation [1].

F9170, an antiviral peptide derived from the HIV-1 envelope glycoprotein (amino acids 789-803), targets the LLP1 domain in the virus's envelope protein cytoplasmic tail. This interaction inhibits HIV-1 IIIB infection in MT-2 cells, evidenced by an EC50 value of 0.19 µM. Additionally, at a dosage of 3 mg/kg, F9170 significantly lowers plasma viral load in rhesus macaques infected with simian HIV (SHIV).

Paquinimod-D5-1 is the deuterated form of Paquinimod. Paquinimod (T7310) (ABR 215757) is an orally active, specific inhibitor of S100A8/S100A9, used in studying pneumonia by reducing viral load in mice infected with SARS-CoV-2.

Foryshiyanine A is a triterpenoid alkaloid with notable biological activities. It exhibits anti-inflammatory properties by inhibiting β-glucuronidase release from rat polymorphonuclear leukocytes. Additionally, Foryshiyanine A demonstrates antiviral activity, with an EC50 value of 4.5 μM against respiratory syncytial virus (RSV) and an IC50 value of 7.3 μM against the influenza A H1N1 virus. It reduces viral load by interfering with viral replication and entry, making it useful for studying inflammation and infection.